Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis

Alexandre Karras*, Christian Pagnoux, Marion Haubitz, Kirsten de Groot, Xavier Puechal, Jan Willem Cohen Tervaert, Marten Segelmark, Loic Guillevin, David Jayne, European Vasculitis Soc

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1662-1668
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume76
Issue number10
DOIs
Publication statusPublished - Oct 2017

Keywords

  • ANTIBODY-ASSOCIATED VASCULITIS
  • SYSTEMIC VASCULITIDES
  • MAINTENANCE THERAPY
  • RENAL SURVIVAL
  • RISK-FACTORS
  • AZATHIOPRINE
  • RELAPSE
  • PROTEINASE-3
  • INDUCTION
  • DAMAGE

Cite this

Karras, A., Pagnoux, C., Haubitz, M., de Groot, K., Puechal, X., Tervaert, J. W. C., Segelmark, M., Guillevin, L., Jayne, D., & European Vasculitis Soc (2017). Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 76(10), 1662-1668. https://doi.org/10.1136/annrheumdis-2017-211123